ecrin-mdr-crcClinical2004advanced/recurrent colorectal cancerAdvanced/recurrent Colorectal CancerInterventionalhttps://newmdr.ecrin.org/Study/2617107Japan2ECRIN MDRActive, not recruitingfalseA multicenter phase I/II study of irinotecan (CPT-11) and S-1 combination chemotherapy for metastatic colorectal cancer (CRC)Interventions: Irinotecan+S-1, repeated every 3 weeks. Primary outcome(s): Phase I : recommended dose Phase I I: Response rate Study Design: Single arm Non-randomized2004-02-152617107JPRN-UMIN000001617